Relevance of nitric oxide for myocardial remodeling

被引：38

作者：

Massion P.B. ^{[1
]}

Balligand J.-L. ^{[1
]}

机构：

[1] Unit of Pharmacology and Therapeutics (FATH 5349), Department of Medicine, Université Catholique de Louvain, 1200 Brussels

来源：

Current Heart Failure Reports | 2007年 / 4卷 / 1期

关键词：

Nitric Oxide; Atrial Natriuretic Peptide; Nebivolol; Arterioscler Thromb Vasc Biol; Celiprolol;

D O I：

10.1007/s11897-007-0021-6

中图分类号：

学科分类号：

摘要：

Endogenous myocardial nitric oxide (NO) may modulate the transition from adaptive to maladaptive remodeling leading to heart failure. In rodent models of pressure overload or myocardial infarction, the three NO synthase (NOS) isoforms were shown to play a neutral, protective, or even adverse role in myocardial remodeling, depending on the quantity of NO produced, the location of each NOS and their regulators, the prevailing oxidant stress and resultant NO/oxidant balance, as well as NOS coupling/dimerization. Beside neuronal NOS and - in specific conditions - inducible NOS isoforms, endothelial NOS (eNOS) exerts cardioprotective effects on pressure-overload, ischemia/reperfusion, and myocardial infarction-induced myocardial remodeling, provided the enzyme remains in a coupled state. Besides its effects on excitation-contraction coupling in response to stretch, eNOS acts as an "endogenous β-blocker" by restoring the sympathovagal balance, opposing excessive hypertrophy as well as promoting vasodilatation and neoangiogenesis, thereby contributing to tissue repair. As eNOS was also shown to mediate the beneficial effects of cardiovascular drugs commonly used in patients with heart failure, strategies to increase its expression and/or coupled catalytic activity in the myocardium offer new therapeutic avenues for the treatment of this disease. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：18 / 25

页数：7

共 75 条

[1]

Pfeffer J.M., Pfeffer M.A., Braunwald E., Influence of chronic captopril therapy on the infarcted left ventricle of the rat, Circ Res, 57, pp. 84-95, (1985)

[2]

Morita H., Seidman J., Seidman C.E., Genetic causes of human heart failure, J Clin Invest, 115, pp. 518-526, (2005)

[3]

McKinsey T.A., Olson E.N., Toward transcriptional therapies for the failing heart: Chemical screens to modulate genes, J Clin Invest, 115, pp. 538-546, (2005)

[4]

Giordano F.J., Oxygen, oxidative stress, hypoxia, and heart failure, J Clin Invest, 115, pp. 500-508, (2005)

[5]

Nian M., Lee P., Khaper N., Et al., Inflammatory cytokines and postmyocardial infarction remodeling, Circ Res, 94, pp. 1543-1553, (2004)

[6]

Dorn G.W., Force T., Protein kinase cascades in the regulation of cardiac hypertrophy, J Clin Invest, 115, pp. 527-537, (2005)

[7]

Opie L.H., Commerford P.J., Gersh B.J., Et al., Controversies in ventricular remodeling, Lancet, 367, pp. 356-367, (2006)

[8]

Webb C.S., Bonnema D.D., Ahmed S.H., Et al., Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling, Circulation, 114, pp. 1020-1027, (2006)

[9]

Heymans S., Schroen B., Vermeersch P., Et al., Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart, Circulation, 112, pp. 1136-1144, (2005)

[10]

Yano M., Ikeda Y., Matsuzaki M., Altered intracellular Ca2+ handling in heart failure, J Clin Invest, 115, pp. 556-564, (2005)

← 1 2 3 4 5 6 7 8 →